<DOC>
	<DOCNO>NCT00001457</DOCNO>
	<brief_summary>Chronic hepatitis B disease liver cause hepatitis B virus . It affect nearly 1 million Americans . Approximately 25 % patient chronic hepatitis B develop liver cirrhosis 5 % patient develop liver cancer . Presently , two medication show effective treatment hepatitis B : lamivudine alpha interferon . Alpha interferon ( antiviral drug act immune system ) give injection daily three time week four six month . Lamivudine ( also know 3-thiacytidine : 3TC ) antiviral medication give pill day twelve month . These treatment know provide long-term improvement one third patient receive . In previous research , drug lamivudine show stop growth hepatitis B virus lead mark decrease level hepatitis B virus improvement disease 50 70 % patient . However , lamivudine therapy discontinue virus return level note therapy begin . In study lamivudine give 3 12 month discontinue . This study investigate safety effectiveness long-term therapy lamivudine . This study select 60 patient diagnosed hepatitis B . After thorough medical examination liver biopsy , subject give lamivudine . The drug take mouth tablet form ( 100 mg ) day 5 year . Subjects undergo regular check-ups 1 year therapy admit Clinical Center another medical examination liver biopsy ass progress . Patients benefit therapy continue take medication 5 year . A third liver biopsy do last year treatment . The effectiveness lamivudine determine whether level hepatitis B virus decrease blood , whether liver enzyme improve , whether inflammation scar decrease liver biopsy .</brief_summary>
	<brief_title>Lamivudine Chronic Hepatitis B</brief_title>
	<detailed_description>To assess safety , antiviral activity clinical benefit lamivudine ( 3-thiacytidine : 3TC ) chronic hepatitis B , treat 60 patient oral lamivudine dose 100 mg daily five year . Lamivudine nucleoside analogue use extensively patient HIV infection study controlled trial chronic hepatitis B . In study , evaluate lamivudine patient four different form chronic hepatitis B : ( A ) Atypical serology ( HBeAg negative ) , ( B ) extra-hepatic manifestation , ( C ) chronic delta hepatitis , ( D ) typical HBeAg- positive chronic hepatitis B . After evaluation liver biopsy , patient receive lamivudine , 100 mg orally daily 1 year , monitor regular interval symptoms liver disease , side effect lamivudine , serum biochemical hematologic index , serologic marker hepatitis B ( D ) virus replication . At one year , patient repeat medical evaluation liver biopsy . If virologic , biochemical histologic evidence benefit , therapy continue thereafter 5 year . Patients develop viral resistance lamivudine may offer therapy high dos lamivudine ( 300 mg per day ) . The activity lamivudine assess change level HBV DNA HDV RNA treatment efficacy loss viral marker improvement aminotransferases liver histology .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Glomerulonephritis</mesh_term>
	<mesh_term>Hepatitis D</mesh_term>
	<mesh_term>Polyarteritis Nodosa</mesh_term>
	<mesh_term>Hepatitis D , Chronic</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>INCLUSION CRITERIA Age 18 year , male female . Known presence HBsAg serum least 6 month . Liver biopsy histology show chronic hepatitis without cirrhosis . Previous therapy alpha interferon without last effect intolerance alpha interferon , due side effect . Written informed consent . Group A : For patient chronic hepatitis B atypical serology : absence HBeAg serum despite elevation serum aminotransferase , average level great 55 U/L ( approximately 1.3 time upper limit normal range ) base upon two determination take least one month apart 6 month entry . Group B : For patient glomerulonephritis : proteinuria great 1 gm per 24 hour . For patient polyarteritis , radiological proof arteritis involvement least organ system outside liver . Group C : For patient chronic delta hepatitis : antiHDV serum HDV antigen liver biopsy HDV RNA serum elevation serum aminotransferase , average level great 55 U/L base upon two determination take least one month apart 6 month entry . Group D : For patient chronic hepatitis B typical serology : HBeAg HBV DNA serum ineligibility enter multicenter trial lamivudine either previous receipt interferon intolerable side effect , refusal receive interferon , normal serum aminotransferase , lack availability trial . EXCLUSION CRITERIA Pregnant capable bearing father child must practice adequate contraception . Significant systemic illness liver disease , include congestive heart failure , renal failure , chronic pancreatitis , diabetes mellitus poor control . Preexisting bone marrow compromise : hematocrit must great 30 % , white blood cell count must great 2000 mm ( 3 ) , platelet must great 70,000 mm ( 3 ) . Creatinine clearance must great 50 cc/min . A history clinically apparent pancreatitis evidence subclinically pancreatitis show serum amylase value twice upper limit normal range abnormality pancreas computerize tomography image study abdomen . Irreversibly severe cirrhosis define Child 's stage C. Presence antiHIV antiHCV HCV RNA serum . Immunosuppressive therapy require use 10 mg prednisone ( equivalent ) per day . Other antiviral therapy chronic hepatitis B within previous 3 month . Sensory motor neuropathy apparent medical history physical examination .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>Nucleoside Analogues</keyword>
	<keyword>Delta Hepatitis</keyword>
	<keyword>Glomerulonephritis</keyword>
	<keyword>Polyarteritis Nodosa</keyword>
	<keyword>Hepatitis Mutants</keyword>
	<keyword>3TC</keyword>
	<keyword>Chronic Hepatitis B</keyword>
	<keyword>Chronic Hepatitis D</keyword>
	<keyword>Cirrhosis</keyword>
	<keyword>Lamivudine</keyword>
</DOC>